C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial

Edith A. Perez, Robert B. Jenkins, Amylou C. Dueck, Anne E. Wiktor, Patrick P. Bedroske, S. Keith Anderson, Rhett P. Ketterling, William R. Sukov, Kazunori Kanehira, Beiyun Chen, Xochiquetzal J. Geiger, Cathy A. Andorfer, Ann E. McCullough, Nancy E. Davidson, Silvana Martino, George W. Sledge, Peter A. Kaufman, Leila A. Kutteh, Julie R. Gralow, Lyndsay N. HarrisJames N. Ingle, Wilma L. Lingle, Monica M. Reinholz

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial'. Together they form a unique fingerprint.

Medicine & Life Sciences